Stones: Epidemiology and Pathogenesis: Difference between revisions
Urology4all (talk | contribs) |
Urology4all (talk | contribs) |
||
(34 intermediate revisions by the same user not shown) | |||
Line 12: | Line 12: | ||
== Physiochemistry and Pathogenesis == | == Physiochemistry and Pathogenesis == | ||
* '''Urine must be supersaturated for stones to form; supersaturation alone is not sufficient for crystallization to occur in urine due to the presence of urinary inhibitors''' | * '''<span style="color:#ff0000">Urine must be supersaturated for stones to form; however, supersaturation alone is not sufficient for crystallization to occur in urine due to the presence of urinary inhibitors</span>''' | ||
** The state of saturation of the urine with respect to particular stone-forming salts indicates the stone-forming propensity of the urine. The state of saturation is determined by pH and the ionic strength of the major ions in solution. | ** The state of saturation of the urine with respect to particular stone-forming salts indicates the stone-forming propensity of the urine. The state of saturation is determined by pH and the ionic strength of the major ions in solution. | ||
** The solubility product refers to the point of saturation where dissolved and crystalline components in solution are in equilibrium. Addition of more crystals to the solution will result in precipitation of crystals. In this supersaturated urine (metastable state), crystallization can occur on preexisting crystals, but spontaneous crystallization occurs only when the concentration product exceeds the formation product. In the supersaturated state, the presence of inhibitors prevents or delays crystallization. | ** The solubility product refers to the point of saturation where dissolved and crystalline components in solution are in equilibrium. Addition of more crystals to the solution will result in precipitation of crystals. In this supersaturated urine (metastable state), crystallization can occur on preexisting crystals, but spontaneous crystallization occurs only when the concentration product exceeds the formation product. In the supersaturated state, the presence of inhibitors prevents or delays crystallization. | ||
*** The process by which nuclei form in pure solutions is called homogeneous nucleation. | *** The process by which nuclei form in pure solutions is called homogeneous nucleation. | ||
*** Heterogeneous nucleation occurs when microscopic impurities or other constituents in the urine promote nucleation by providing a surface on which the crystal components can grow. | *** Heterogeneous nucleation occurs when microscopic impurities or other constituents in the urine promote nucleation by providing a surface on which the crystal components can grow. | ||
** '''Known inhibitors of calcium oxalate and calcium phosphate crystallization (6) No More Bad Colicky Torturous Urolithiasis:''' | ** '''<span style="color:#ff0000">Known inhibitors of calcium oxalate and calcium phosphate crystallization (6) </span><span style="color:#0000ff">No More Bad Colicky Torturous Urolithiasis:</span>''' | ||
**# ''' | **# '''<span style="color:#0000ff">N</span><span style="color:#ff0000">ephrocalcin</span>''' | ||
**# ''' | **# '''<span style="color:#0000ff">M</span><span style="color:#ff0000">agnesium</span>''' | ||
**#* Inhibitory activity derived from its complexation with oxalate, which reduces ionic oxalate concentration and calcium oxalate supersaturation | **#* Inhibitory activity derived from its complexation with oxalate, which reduces ionic oxalate concentration and calcium oxalate supersaturation | ||
**# ''' | **# '''<span style="color:#0000ff">B</span><span style="color:#ff0000">ikunin</span>''' | ||
**# ''' | **# '''<span style="color:#0000ff">C</span><span style="color:#ff0000">itrate</span>''' | ||
**#* '''Most important factor''' | **#* '''<span style="color:#ff0000">Most important factor</span>''' | ||
**#* '''MOA:''' | **#* '''MOA (4):''' | ||
**#*# '''Complexes calcium''', thereby lowering urinary saturation of calcium oxalate | **#*# '''Complexes calcium''', thereby lowering urinary saturation of calcium oxalate | ||
**#*# Inhibits spontaneous precipitation of calcium oxalate and agglomeration of calcium oxalate crystals | **#*# Inhibits spontaneous precipitation of calcium oxalate and agglomeration of calcium oxalate crystals | ||
**#*# Inhibits calcium oxalate and calcium phosphate crystal growth, with effect on calcium phosphate crystal growth more pronounced than on calcium oxalate crystal growth | **#*# Inhibits calcium oxalate and calcium phosphate crystal growth, with effect on calcium phosphate crystal growth more pronounced than on calcium oxalate crystal growth | ||
**#*# Prevents heterogeneous nucleation of calcium oxalate by monosodium urate | **#*# Prevents heterogeneous nucleation of calcium oxalate by monosodium urate | ||
**# ''' | **# '''<span style="color:#0000ff">T</span><span style="color:#ff0000">amm-Horsfall mucoprotein</span>''' | ||
**#* '''Most abundant protein in the urine''' | **#* '''Most abundant protein in the urine''' | ||
**# ''' | **# '''<span style="color:#0000ff">U</span><span style="color:#ff0000">ropontin</span>''' | ||
** '''No known inhibitors affect uric acid crystallization''' | ** '''No known inhibitors affect uric acid crystallization''' | ||
* '''Renal calculi consist of 2 components: crystalline and non-crystalline (matrix) components''' | * '''<span style="color:#ff0000">Renal calculi consist of 2 components: crystalline and non-crystalline (matrix) components</span>''' | ||
** '''Crystalline''' | ** '''<span style="color:#ff0000">Crystalline</span>''' | ||
*** '''Calcium is the most common component of urinary calculi''' | *** '''<span style="color:#ff0000">Calcium is the most common component of urinary calculi</span>''' | ||
** '''Non-crystalline (matrix)''' | ** '''<span style="color:#ff0000">Non-crystalline (matrix)</span>''' | ||
*** '''Typically accounts for 2.5% of the weight of the stone.''' | *** '''Typically accounts for 2.5% of the weight of the stone.''' | ||
*** '''Matrix is a heterogenous mixture consisting of ≈65% protein.''' '''Other components include mucoproteins, carbohydrates, and urinary inhibitor''' | *** '''<span style="color:#ff0000">Matrix is a heterogenous mixture consisting of ≈65% protein.</span>''' '''Other components include mucoproteins, carbohydrates, and urinary inhibitor''' | ||
* '''In idiopathic calcium oxalate stone formers, Randall plaques, which are composed of calcium apatite, have been found to originate in the basement membrane of the thin loops of Henle. From there, they extend through the medullary interstitium to a subepithelial location, where they serve as an anchoring site for calcium oxalate stone formation.''' | * '''<span style="color:#ff0000">In idiopathic calcium oxalate stone formers, Randall plaques, which are composed of calcium apatite, have been found to originate in the basement membrane of the thin loops of Henle.</span> From there, they extend through the medullary interstitium to a subepithelial location, where they serve as an anchoring site for calcium oxalate stone formation.''' | ||
== Mineral metabolism == | == Mineral metabolism == | ||
=== Calcium === | === Calcium === | ||
* '''30-40% of dietary calcium is absorbed from the intestine, with most being absorbed in the small intestine and only ≈10% absorbed in the colon''' | * '''<span style="color:#ff0000">30-40% of dietary calcium is absorbed from the intestine, with most being absorbed in the small intestine and only ≈10% absorbed in the colon</span>''' | ||
* '''Absorption of calcium varies with calcium intake by a process of intestinal adaptation''' - at times of low calcium intake, fractional calcium absorption is enhanced; during high calcium intake, fractional calcium absorption is reduced | * '''Absorption of calcium varies with calcium intake by a process of intestinal adaptation''' - at times of low calcium intake, fractional calcium absorption is enhanced; during high calcium intake, fractional calcium absorption is reduced | ||
* '''Substances that complex with calcium, such as oxalate, citrate, phosphate, sulfate, and fatty acids, reduce the availability of calcium for absorption''' | * '''<span style="color:#ff0000">Substances that complex with calcium, such as oxalate, citrate, phosphate, sulfate, and fatty acids, reduce the availability of calcium for absorption</span>''' | ||
* '''Calcium homeostasis''' | * '''<span style="color:#ff0000">Calcium homeostasis</span>''' | ||
** '''PTH''' | ** '''<span style="color:#ff0000">PTH</span>''' | ||
*** '''Secreted in response to low serum calcium''' | *** '''<span style="color:#ff0000">Secreted in response to low serum calcium</span>''' | ||
*** '''Functions (3):''' | *** '''Functions (3):''' | ||
***# '''Increases renal reabsorption of calcium and reduces reabsorption of phosphate from distal tubule (primary effect)''' | ***# '''Increases renal reabsorption of calcium and reduces reabsorption of phosphate from distal tubule (primary effect)''' | ||
Line 83: | Line 83: | ||
== Classification of nephrolithiasis == | == Classification of nephrolithiasis == | ||
* '''Calcium-containing stones''' | * '''<span style="color:#ff0000">Calcium-containing stones</span>''' | ||
*# '''Calcium oxalate (60%)''' | *# '''<span style="color:#ff0000">Calcium oxalate (60%)</span>''' | ||
*# '''Hydroxyapatite (20%)''' | *# '''<span style="color:#ff0000">Hydroxyapatite</span> (20%)''' | ||
*# '''Brushite (2%)''' | *# '''<span style="color:#ff0000">Calcium Phosphate/Brushite</span> (2%)''' | ||
* '''Non-calcium containing stones''' | * '''<span style="color:#ff0000">Non-calcium containing stones</span>''' | ||
*# '''Uric acid (7%)''' | *# '''<span style="color:#ff0000">Uric acid</span> (7%)''' | ||
*# '''Struvite (7%)''' | *# '''<span style="color:#ff0000">Struvite</span> (7%)''' | ||
*# '''Cystine (1-3%)''' | *# '''<span style="color:#ff0000">Cystine</span> (1-3%)''' | ||
*# '''Triamterene (<1%)''' | *# '''<span style="color:#ff0000">Triamterene</span> (<1%)''' | ||
*# '''Silica (<1%)''' | *# '''<span style="color:#ff0000">Silica</span> (<1%)''' | ||
*# '''2,8-dihydroxyadenine (<1%)''' | *# '''<span style="color:#ff0000">2,8-dihydroxyadenine</span> (<1%)''' | ||
== Calcium stones == | == Calcium stones == | ||
Line 100: | Line 100: | ||
=== Hypercalcuria === | === Hypercalcuria === | ||
* '''Most common abnormality identified in calcium stone formers''' | * '''<span style="color:#ff0000">Most common abnormality identified in calcium stone formers</span>''' | ||
** '''Recall, hypercalcuria is the most common cause of microscopic hematuria in children''' | ** '''Recall, hypercalcuria is the most common cause of microscopic hematuria in children''' | ||
* '''Classification:''' | * '''<span style="color:#ff0000">Classification:</span>''' | ||
*# '''Absorptive hypercalcuria''' | *# '''<span style="color:#ff0000">Absorptive hypercalcuria</span>''' | ||
*#* '''Characterized by''' | *#* '''Characterized by''' | ||
*#*# '''Normal serum calcium''' | *#*# '''Normal serum calcium''' | ||
Line 113: | Line 113: | ||
*#** '''Absorptive hypercalciuria type I: increased absorption will occur regardless of the amount of calcium in the diet'''. Therefore, these subjects will demonstrate an increased urinary excretion of calcium on both the fasting and the loading specimens. | *#** '''Absorptive hypercalciuria type I: increased absorption will occur regardless of the amount of calcium in the diet'''. Therefore, these subjects will demonstrate an increased urinary excretion of calcium on both the fasting and the loading specimens. | ||
*#** '''Absorptive hypercalciuria type II: normal amount of urinary calcium excretion during calcium restriction''', but will show elevations during their regular diet | *#** '''Absorptive hypercalciuria type II: normal amount of urinary calcium excretion during calcium restriction''', but will show elevations during their regular diet | ||
*# '''Renal (leak) hypercalcuria''' | *# '''<span style="color:#ff0000">Renal (leak) hypercalcuria</span>''' | ||
*#* '''Characterized by''' | *#* '''Characterized by''' | ||
*#*# '''Normal serum calcium''' | *#*# '''Normal serum calcium''' | ||
Line 123: | Line 123: | ||
*#** Serum calcium levels remain normal because the renal loss of calcium is compensated by enhanced intestinal absorption of calcium and bone resorption as a result of increased secretion of PTH | *#** Serum calcium levels remain normal because the renal loss of calcium is compensated by enhanced intestinal absorption of calcium and bone resorption as a result of increased secretion of PTH | ||
*#** '''The elevated serum PTH and elevated fasting urinary calcium (except if absorptive hypercalciuria I) levels differentiate renal from absorptive hypercalciuria''' | *#** '''The elevated serum PTH and elevated fasting urinary calcium (except if absorptive hypercalciuria I) levels differentiate renal from absorptive hypercalciuria''' | ||
*# '''Resorptive hypercalcuria''' | *# '''<span style="color:#ff0000">Resorptive hypercalcuria</span>''' | ||
*#* Infrequent abnormality; '''most commonly associated with primary hyperparathyroidism''' | *#* Infrequent abnormality; '''most commonly associated with primary hyperparathyroidism''' | ||
*#* '''Characterized by:''' | *#* '''Characterized by:''' | ||
Line 135: | Line 135: | ||
*#* '''Additional, rare causes of resorptive hypercalciuria include hypercalcemia of malignancy, sarcoidosis''', '''thyrotoxicosis, and vitamin D toxicity'''. Many granulomatous diseases, including tuberculosis, histoplasmosis, leprosy, and silicosis, have been reported to produce hypercalcemia. | *#* '''Additional, rare causes of resorptive hypercalciuria include hypercalcemia of malignancy, sarcoidosis''', '''thyrotoxicosis, and vitamin D toxicity'''. Many granulomatous diseases, including tuberculosis, histoplasmosis, leprosy, and silicosis, have been reported to produce hypercalcemia. | ||
*#** The hypercalcemia in sarcoidosis is due to the production of 1,25(OH)2D3 from 1α-hydroxylase present in macrophages of the sarcoid granuloma | *#** The hypercalcemia in sarcoidosis is due to the production of 1,25(OH)2D3 from 1α-hydroxylase present in macrophages of the sarcoid granuloma | ||
*# '''Idiopathic (unclassified) hypercalcuria''' | *# '''<span style="color:#ff0000">Idiopathic (unclassified) hypercalcuria</span>''' | ||
*#* Often refers to unevaluated or unknown cause | *#* Often refers to unevaluated or unknown cause | ||
*#* Patients may demonstrate hypercalcuria in all phases of the dietary calcium manipulation, but will not demonstrate serum abnormalities | *#* Patients may demonstrate hypercalcuria in all phases of the dietary calcium manipulation, but will not demonstrate serum abnormalities | ||
*# '''Malignancy-associated hypercalemia''' | *# '''<span style="color:#ff0000">Malignancy-associated hypercalemia</span>''' | ||
*#* An assay for intact PTH can help distinguish patients with hyperparathyroidism from those with other causes of hypercalcuria. Tumours in patients with humoral hypercalcemia produce a PTH-related protein (PTHrP) | *#* An assay for intact PTH can help distinguish patients with hyperparathyroidism from those with other causes of hypercalcuria. Tumours in patients with humoral hypercalcemia produce a PTH-related protein (PTHrP) | ||
*# '''Glucocorticoid-induced hypercalemia''' | *# '''<span style="color:#ff0000">Glucocorticoid-induced hypercalemia</span>''' | ||
=== Hyperoxaluria === | === Hyperoxaluria === | ||
* '''Classification (4):''' | * '''<span style="color:#ff0000">Classification (4):</span>''' | ||
*# '''Primary hyperoxaluria''' | *# '''<span style="color:#ff0000">Primary hyperoxaluria</span>''' | ||
*#* Due to '''rare autosomal recessive inherited disorders in glyoxylate metabolism''', '''leading to preferential oxidative conversion of glyoxylate to oxalate''', an end product of metabolism | *#* Due to '''rare autosomal recessive inherited disorders in glyoxylate metabolism''', '''leading to preferential oxidative conversion of glyoxylate to oxalate''', an end product of metabolism | ||
*# '''Enteric hyperoxaluria''' | *# '''<span style="color:#ff0000">Enteric hyperoxaluria</span>''' | ||
*#* '''In patients with enteric hyperoxaluria, intestinal hyperabsorption of oxalate is the most significant risk factor leading to recurrent calculus formation''' | *#* '''In patients with enteric hyperoxaluria, intestinal hyperabsorption of oxalate is the most significant risk factor leading to recurrent calculus formation''' | ||
*#** '''Fat malabsorption results in increased intestinal oxalate absorption''' | *#** '''<span style="color:#ff0000">Fat malabsorption results in increased intestinal oxalate absorption</span>''' | ||
*#*** '''In fat malabsorption, saponification of fatty acids occurs with divalent cations such as calcium''' and magnesium, '''which reduces calcium available for complexation with oxalate''' thereby resulting in an increased amount of oxalate available for reabsorption. | *#*** '''In fat malabsorption, saponification of fatty acids occurs with divalent cations such as calcium''' and magnesium, '''which reduces calcium available for complexation with oxalate''' thereby resulting in an increased amount of oxalate available for reabsorption. | ||
*#*** '''The poorly absorbed fatty acids and bile salts may increase colonic permeability to oxalate, further enhancing intestinal oxalate absorption''' | *#*** '''The poorly absorbed fatty acids and bile salts may increase colonic permeability to oxalate, further enhancing intestinal oxalate absorption''' | ||
*#*** '''Patients with enteric hyperoxaluria are more likely to form calcium oxalate stones,''' due to increased urinary excretion of oxalate and decreased inhibitory activity from hypocitraturia, secondary to chronic metabolic acidosis and hypomagnesuria. | *#*** '''<span style="color:#ff0000">Patients with enteric hyperoxaluria are more likely to form calcium oxalate stones,</span>''' due to increased urinary excretion of oxalate and decreased inhibitory activity from hypocitraturia, secondary to chronic metabolic acidosis and hypomagnesuria. | ||
*#** '''Malabsorption of any cause (chronic diarrheal states, inflammatory bowel disease, celiac sprue, or intestinal resection) can lead to increased intestinal absorption of oxalate and hyperoxaluria; as a result of intestinal fluid loss, patients will often exhibit dehydration, bicarbonate losses, low urine volume''' | *#** '''<span style="color:#ff0000">Malabsorption of any cause (chronic diarrheal states, inflammatory bowel disease, celiac sprue, or intestinal resection)</span> can lead to increased intestinal absorption of oxalate and hyperoxaluria; as a result of intestinal fluid loss, patients will often exhibit dehydration, bicarbonate losses, low urine volume''' | ||
*#*** '''Hyperoxaluria has been described in''' both stone-forming and non-stone-forming patients who have undergone '''Roux-en-Y gastric bypass surgery,''' with urinary oxalate levels in some patients exceeding 100 mg/day | *#*** '''Hyperoxaluria has been described in''' both stone-forming and non-stone-forming patients who have undergone '''Roux-en-Y gastric bypass surgery,''' with urinary oxalate levels in some patients exceeding 100 mg/day | ||
*#**** '''Bariatric surgery patients typically develop enteric hyperoxaluria, which should be managed with calcium supplementation''' | *#**** '''<span style="color:#ff0000">Bariatric surgery patients typically develop enteric hyperoxaluria, which should be managed with calcium supplementation</span>''' | ||
*#***** '''Iron deficiency is the most common cause of anemia following bariatric surgery,''' particularly in premenopausal women. | *#***** '''Iron deficiency is the most common cause of anemia following bariatric surgery,''' particularly in premenopausal women. | ||
*#*** '''Chronic diarrheal syndromes promote intestinal loss of alkali and dehydration, resulting in metabolic acidosis and reduced urinary citrate levels.''' | *#*** '''<span style="color:#ff0000">Chronic diarrheal syndromes</span> promote intestinal loss of alkali and dehydration, resulting in metabolic acidosis and reduced urinary citrate levels.''' | ||
*#**** '''Chronic metabolic acidosis can lead to low urine pH, hypercalciuria, and hypocitraturia.''' | *#**** '''Chronic metabolic acidosis can lead to low urine pH, hypercalciuria, and hypocitraturia.''' | ||
*#* '''Restricting oxalate is generally insufficient as the cause is not an overabundance of oxalate''' | *#* '''Restricting oxalate is generally insufficient as the cause is not an overabundance of oxalate''' | ||
*# '''Dietary hyperoxaluria''' | *# '''<span style="color:#ff0000">Dietary hyperoxaluria</span>''' | ||
*#* '''Overindulgence in oxalate-rich foods such as (Oxalate Rich Chocolate, Pepper, Nuts): Okra, Rhubarb, Chocolate, Pepper, Nuts, Tea (black), cocoa, spinach, mustard greens, pokeweed, swiss chard, beets, berries, wheat germ, and soy crackers can result in hyperoxaluria in otherwise normal individuals.''' | *#* '''<span style="color:#ff0000">Overindulgence in oxalate-rich foods such as (Oxalate Rich Chocolate, Pepper, Nuts): Okra, Rhubarb, Chocolate, Pepper, Nuts, Tea (black), cocoa, spinach, mustard greens, pokeweed, swiss chard, beets, berries, wheat germ, and soy crackers can result in hyperoxaluria in otherwise normal individuals.</span>''' | ||
*#** Compliance is difficult for regimens intending to eliminate all oxalate sources | *#** Compliance is difficult for regimens intending to eliminate all oxalate sources | ||
*#* '''Severe calcium restriction may result in reduced intestinal binding of oxalate and increased intestinal oxalate absorption, hence calcium intake should be moderate, rather than restricted''' | *#* '''<span style="color:#ff0000">Severe calcium restriction may result in reduced intestinal binding of oxalate and increased intestinal oxalate absorption, hence calcium intake should be moderate, rather than restricted</span>''' | ||
*#** '''Increasing calcium intake, which may include supplements, specifically timed with meals, may reduce hyperoxaluria''' | *#** '''<span style="color:#ff0000">Increasing calcium intake, which may include supplements, specifically timed with meals, may reduce hyperoxaluria</span>''' | ||
*#* '''High substrate levels (vitamin C) can also cause hyperoxaluria;''' doses should be limited to 2 g/day | *#* '''<span style="color:#ff0000">High substrate levels (vitamin C) can also cause hyperoxaluria;</span>''' doses should be limited to 2 g/day | ||
*# '''Idiopathic hyperoxaluria''' | *# '''<span style="color:#ff0000">Idiopathic hyperoxaluria</span>''' | ||
=== Hyperuricosuria === | === Hyperuricosuria === | ||
* '''May be associated with pure uric acid calculi or calcium oxalate calculi through heterogenous nucleation''' | * '''<span style="color:#ff0000">May be associated with pure uric acid calculi or calcium oxalate calculi through heterogenous nucleation</span>''' | ||
** '''Patients with hyperuricosuric calcium nephrolithiasis who form calcium oxalate stones present with normal urinary pH and hyperuricosuria, accompanied sometimes by hypercalciuria''' | ** '''Patients with hyperuricosuric calcium nephrolithiasis who form calcium oxalate stones present with normal urinary pH and hyperuricosuria, accompanied sometimes by hypercalciuria''' | ||
** In contrast, those with gouty diathesis, who can form either uric acid or calcium oxalate calculi, have a low fractional excretion of urate (that contributes to hyperuricemia) and low urinary pH (that leads to increased amount of undissociated uric acid) | ** In contrast, those with gouty diathesis, who can form either uric acid or calcium oxalate calculi, have a low fractional excretion of urate (that contributes to hyperuricemia) and low urinary pH (that leads to increased amount of undissociated uric acid) | ||
* '''Causes:''' | * '''<span style="color:#ff0000">Causes:</span>''' | ||
*# '''Increased dietary purine intake (most common cause)''' | *# '''<span style="color:#ff0000">Increased dietary purine intake (most common cause)</span>''' | ||
*# '''Gout''' | *# '''<span style="color:#ff0000">Gout</span>''' | ||
*# '''Myeloproliferative and lymphoproliferative disorders''' | *# '''<span style="color:#ff0000">Myeloproliferative and lymphoproliferative disorders</span>''' | ||
*# '''Multiple myeloma''' | *# '''<span style="color:#ff0000">Multiple myeloma</span>''' | ||
*# '''Thalassemia''' | *# '''<span style="color:#ff0000">Thalassemia</span>''' | ||
*# '''Hemolytic disorders''' | *# '''<span style="color:#ff0000">Hemolytic disorders</span>''' | ||
*# '''Pernicious anemia''' | *# '''<span style="color:#ff0000">Pernicious anemia</span>''' | ||
*# '''Hemoglobinopathies''' | *# '''<span style="color:#ff0000">Hemoglobinopathies</span>''' | ||
*# '''Secondary polycythemia''' | *# '''<span style="color:#ff0000">Secondary polycythemia</span>''' | ||
*# '''Complete or partial hypoxanthine-guanine phosphoribosyltransferase (HGPRT) deficiency''' | *# '''<span style="color:#ff0000">Complete or partial hypoxanthine-guanine phosphoribosyltransferase (HGPRT) deficiency</span>''' | ||
*#* Lesch-Nyhan syndrome is an inherited deficiency of the purine salvage enzyme hypoxanthine-guanine phosphoribosyltransferase, which leads to the accumulation of hypoxanthine, which is ultimately converted to uric acid | *#* Lesch-Nyhan syndrome is an inherited deficiency of the purine salvage enzyme hypoxanthine-guanine phosphoribosyltransferase, which leads to the accumulation of hypoxanthine, which is ultimately converted to uric acid | ||
*# '''Overactivity of phosphoribosylpyrophosphate synthetase''' | *# '''<span style="color:#ff0000">Overactivity of phosphoribosylpyrophosphate synthetase</span>''' | ||
*# '''Hereditary renal hypouricemia''' | *# '''<span style="color:#ff0000">Hereditary renal hypouricemia</span>''' | ||
=== Renal tubular acidosis (RTA) === | === Renal tubular acidosis (RTA) === | ||
* '''RTA is a clinical syndrome characterized by metabolic acidosis''' | * '''RTA is a clinical syndrome characterized by metabolic acidosis''' | ||
* '''Classified: acquired vs. inherited | * '''Classified: acquired vs. inherited''' | ||
** '''Causes of acquired RTA A CASH POT''' | ** '''Causes of acquired RTA: A CASH POT''' | ||
*# '''Analgesic nephropathy''' | *# '''Analgesic nephropathy''' | ||
*# '''Idiopathic hyperCalciuria''' | *# '''Idiopathic hyperCalciuria''' | ||
Line 198: | Line 198: | ||
*# '''Obstructive uropathy''' | *# '''Obstructive uropathy''' | ||
*# '''Transplant (renal)''' | *# '''Transplant (renal)''' | ||
* '''3 types: type 1 (distal), type 2 (proximal), and type 4 (distal)''' | * '''<span style="color:#ff0000">3 types: type 1 (distal), type 2 (proximal), and type 4 (distal)</span>''' | ||
*# '''Type 1 (distal) RTA''' | *# '''<span style="color:#ff0000">Type 1 (distal) RTA</span>''' | ||
*#* '''Most common form of RTA and most commonly associated with kidney stones''' (up to 70% of adults with type 1 RTA have kidney stones) | *#* '''<span style="color:#ff0000">Most common form of RTA and most commonly associated with kidney stones</span>''' (up to 70% of adults with type 1 RTA have kidney stones) | ||
*#* '''Characterized by (5):''' | *#* '''<span style="color:#ff0000">Characterized by (5):</span>''' | ||
*#*# ''' | *#*# '''<span style="color:#ff0000">Increased urinary pH''' (>6.0) | ||
*#*# ''' | *#*#'''Hyperchloremic, non-anion gap metabolic acidosis''' | ||
*#*# '''Hypercalcuria''' | *#*# </span>'''Hypercalcuria''' | ||
*#*# '''Hypocitraturia''' | *#*# '''Hypocitraturia''' | ||
*#*# '''Hypokalemia''' | *#*# '''Hypokalemia''' | ||
*#** '''Due to impaired acid (H+, hydrogen is first element in periodic table so type 1 ) excretion into the urine in the presence of systemic acidosis, from dysfunction of the alpha-type intercalated cells''', which secrete protons into the urine via an apical H+-ATPase | *#** '''<span style="color:#ff0000">Due to impaired acid (H+, hydrogen is first element in periodic table so type 1 ) excretion into the urine in the presence of systemic acidosis, from dysfunction of the alpha-type intercalated cells</span>''', which secrete protons into the urine via an apical H+-ATPase | ||
*#*** Metabolic acidosis may cause a negative calcium balance as a result of impaired renal tubular reabsorption of calcium in the proximal tubule, leading to excessive renal loss of calcium. In addition, intestinal calcium absorption is diminished in patients with persistent acidosis. Slow dissolution of bone mineral can also be identified as calcium and phosphate act as buffering mechanisms to correct the acidosis. Chronic acidosis has been cited as a major factor in the genesis of bone disease. | *#*** Metabolic acidosis may cause a negative calcium balance as a result of impaired renal tubular reabsorption of calcium in the proximal tubule, leading to excessive renal loss of calcium. In addition, intestinal calcium absorption is diminished in patients with persistent acidosis. Slow dissolution of bone mineral can also be identified as calcium and phosphate act as buffering mechanisms to correct the acidosis. Chronic acidosis has been cited as a major factor in the genesis of bone disease. | ||
*#** Patients with the incomplete form of distal RTA are not persistently acidemic despite their inability to lower urinary pH with an acid load. '''The diagnosis of incomplete distal RTA can be confirmed by inadequate urinary acidification''' after an ammonium chloride loading test. | *#** Patients with the incomplete form of distal RTA are not persistently acidemic despite their inability to lower urinary pH with an acid load. '''The diagnosis of incomplete distal RTA can be confirmed by inadequate urinary acidification''' after an ammonium chloride loading test. | ||
*#* '''Potassium citrate therapy is able to correct the metabolic acidosis and hypokalemia''' | *#* '''Potassium citrate therapy is able to correct the metabolic acidosis and hypokalemia''' | ||
*#* '''Most common stone composition associated with distal RTA is calcium phosphate''' as a result of increased urinary pH, hypercalciuria, and hypocitraturia | *#* '''<span style="color:#ff0000">Most common stone composition associated with Type 1/distal RTA is calcium phosphate</span>''' as a result of increased urinary pH, hypercalciuria, and hypocitraturia | ||
*# '''Type 2 (proximal) RTA''' | *#*'''<span style="color:#ff0000">Associated with nephrocalcinosis on imaging</span>''' | ||
*#* '''Due to impaired bicarbonate (bi=2, type 2) reabsorption''' | *# '''<span style="color:#ff0000">Type 2 (proximal) RTA</span>''' | ||
*#* '''<span style="color:#ff0000">Due to impaired bicarbonate (bi=2, type 2) reabsorption</span>''' | |||
*#* Proximal RTA is characterized by a defect in HCO3− reabsorption associated with initial high urine pH that normalizes as plasma HCO3– decreases and the amount of filtered HCO3– falls. With reduced capacity of the proximal tubule to reclaim filtered HCO3−, more HCO3− is delivered to the distal tubule, which has a limited capacity for bicarbonate reabsorption. Consequently, bicarbonaturia ensues, resulting in reduced net acid excretion and metabolic acidosis. As the filtered HCO3- load declines with progressive metabolic acidosis, less bicarbonate reaches the distal tubule until eventually the capacity of the distal tubule is sufficient to handle the load and no further bicarbonate is lost. '''At steady state, serum HCO3− is low (15 to 18 mEq/L) and urine pH is acidic (<5.5).''' | *#* Proximal RTA is characterized by a defect in HCO3− reabsorption associated with initial high urine pH that normalizes as plasma HCO3– decreases and the amount of filtered HCO3– falls. With reduced capacity of the proximal tubule to reclaim filtered HCO3−, more HCO3− is delivered to the distal tubule, which has a limited capacity for bicarbonate reabsorption. Consequently, bicarbonaturia ensues, resulting in reduced net acid excretion and metabolic acidosis. As the filtered HCO3- load declines with progressive metabolic acidosis, less bicarbonate reaches the distal tubule until eventually the capacity of the distal tubule is sufficient to handle the load and no further bicarbonate is lost. '''At steady state, serum HCO3− is low (15 to 18 mEq/L) and urine pH is acidic (<5.5).''' | ||
*#* '''Nephrolithiasis is uncommon in this disorder as urinary citrate levels are not decreased, in contrast to type 1 RTA''' | *#* '''Nephrolithiasis is uncommon in this disorder as urinary citrate levels are not decreased, in contrast to type 1 RTA''' | ||
Line 221: | Line 222: | ||
*#* Associated with hyperkalemia | *#* Associated with hyperkalemia | ||
*#* '''Nephrolithiasis is uncommon in this disorder''' | *#* '''Nephrolithiasis is uncommon in this disorder''' | ||
=== Hypomagnesiuria === | === Hypomagnesiuria === | ||
Line 277: | Line 240: | ||
=== Urine pH === | === Urine pH === | ||
* '''At low urine pH (<5.5), the undissociated form of uric acid predominates, leading to uric acid and/or calcium stone formation.''' | * '''<span style="color:#ff0000">At low urine pH (<5.5), the undissociated form of uric acid predominates, leading to uric acid and/or calcium stone formation.</span>''' | ||
** '''Any disorder leading to low urine pH may predispose to stone formation.''' | ** '''Any disorder leading to low urine pH may predispose to stone formation.''' | ||
** '''Calcium oxalate stones can form in low urine pH as a result of heterogeneous nucleation with uric acid crystals'''. | ** '''Calcium oxalate stones can form in low urine pH as a result of heterogeneous nucleation with uric acid crystals'''. | ||
Line 283: | Line 246: | ||
== Uric acid stones == | == Uric acid stones == | ||
'''Determinants of uric acid stone formation (3):''' | '''<span style="color:#ff0000">Determinants of uric acid stone formation (3):</span>''' | ||
# '''Low urine pH (<5.5) (most important)''' | # '''<span style="color:#ff0000">Low urine pH (<5.5) (most important)</span>''' | ||
#* Urine pH remains the most cost-effective means of screening for this condition and monitoring therapy. | #* Urine pH remains the most cost-effective means of screening for this condition and monitoring therapy. | ||
# '''Low urine volume''' | # '''<span style="color:#ff0000">Low urine volume</span>''' | ||
# '''Hyperuricosuria''' | # '''<span style="color:#ff0000">Hyperuricosuria</span>''' | ||
=== Causes === | === Causes === | ||
Line 297: | Line 260: | ||
==== Acquired ==== | ==== Acquired ==== | ||
# '''Diabetes''' | # '''<span style="color:#ff0000">Diabetes''' | ||
#* '''Diabetic stone formers have a lower urine pH''' compared with non-diabetic stone formers '''due to insulin resistance''' | #* '''Diabetic stone formers have a lower urine pH''' compared with non-diabetic stone formers '''due to insulin resistance''' | ||
#** In normal individuals, insulin stimulates ammoniagenesis in renal tubule cells by promoting gluconeogenesis from glutamine and by stimulating ammonium excretion by the proximal tubular sodium/hydrogen exchanger. Failure of the renal tubule cells to respond to insulin '''results in defective ammonia production and/or excretion, thereby leading to a reduction in urinary pH and uric acid stone formation'''. | #** In normal individuals, insulin stimulates ammoniagenesis in renal tubule cells by promoting gluconeogenesis from glutamine and by stimulating ammonium excretion by the proximal tubular sodium/hydrogen exchanger. Failure of the renal tubule cells to respond to insulin '''results in defective ammonia production and/or excretion, thereby leading to a reduction in urinary pH and uric acid stone formation'''. | ||
#* '''Diabetic stone formers are approximately 6x more likely to develop a uric acid stone'''. | #* '''Diabetic stone formers are approximately 6x more likely to develop a uric acid stone'''. | ||
#** Uric acid stones are found in 34% of stone-forming patients with diabetes mellitus compared to 6% of non-diabetic stone formers | #** Uric acid stones are found in 34% of stone-forming patients with diabetes mellitus compared to 6% of non-diabetic stone formers | ||
# '''Obesity''' | # '''<span style="color:#ff0000">Obesity</span>''' | ||
# '''Metabolic syndrome''' | # '''<span style="color:#ff0000">Metabolic syndrome</span>''' | ||
# '''Tumour lysis syndrome''' | # '''<span style="color:#ff0000">Tumour lysis syndrome</span>''' | ||
# '''Volume depletion''' | # '''<span style="color:#ff0000">Volume depletion</span>''' | ||
# '''High animal protein intake''' | # '''<span style="color:#ff0000">High animal protein intake</span>''' | ||
# '''Chronic diarrhea''' | # '''<span style="color:#ff0000">Chronic diarrhea</span>''' | ||
# '''Uricosuric drugs''' | # '''<span style="color:#ff0000">Uricosuric drugs</span>''' | ||
# '''Idiopathic''' | # '''<span style="color:#ff0000">Idiopathic</span>''' | ||
* '''All 11 conditions associated with hyperuricosuria listed above''' | * '''<span style="color:#ff0000">All 11 conditions associated with hyperuricosuria listed above</span>''' | ||
== | == Calcium Phosphate Stones == | ||
* '''Stones are considered poorly radioopaque on imaging'''§ | * '''<span style="color:#ff0000">Associated with (4):</span>''' | ||
#'''<span style="color:#ff0000">RTA Type 1</span>''' | |||
#'''<span style="color:#ff0000">Primary hyperparathyroidism</span>''' | |||
#'''<span style="color:#ff0000">Medullary sponge kidney</span>''' | |||
#'''<span style="color:#ff0000">Use of carbonic anhydrase inhibitors</span>''' | |||
== Cystine Stones == | |||
* '''Stones are considered poorly radioopaque on imaging'''[https://uroweb.org/guideline/urolithiasis/ §] | |||
=== Causes === | === Causes === | ||
Line 325: | Line 295: | ||
*** '''Used for screening purposes to identify patients with cystine stone disease''' who are undergoing a 24 hour urine collection for evaluation. | *** '''Used for screening purposes to identify patients with cystine stone disease''' who are undergoing a 24 hour urine collection for evaluation. | ||
== Infection | == Infection Stones (magnesium ammonium phosphate) == | ||
* '''Struvite stones occur only in association with urinary infection by urea-splitting organisms.''' | * '''<span style="color:#ff0000">Struvite stones occur only in association with urinary infection by urea-splitting organisms.</span>''' | ||
** '''Urease hydrolyzes urea, forming ammonium and carbon dioxide, which increases urinary pH.''' | ** '''Urease hydrolyzes urea, forming ammonium and carbon dioxide, which increases urinary pH.''' | ||
*** Alkaline urine promotes supersaturation and precipitation of crystals of magnesium ammonium phosphate and carbonate apatite. | *** Alkaline urine promotes supersaturation and precipitation of crystals of magnesium ammonium phosphate and carbonate apatite. | ||
* '''Most common urease-producing pathogens (4):''' | * '''<span style="color:#ff0000">Most common urease-producing pathogens (4):</span>''' | ||
*# '''Proteus (most common)''' | *# '''<span style="color:#ff0000">Proteus (most common)</span>''' | ||
*# '''Klebsiella''' | *# '''<span style="color:#ff0000">Klebsiella</span>''' | ||
*# '''Pseudomonas''' | *# '''<span style="color:#ff0000">Pseudomonas</span>''' | ||
*# '''Staphylococcus aureus''' | *# '''<span style="color:#ff0000">Staphylococcus aureus</span>''' | ||
** '''Some yeasts and mycoplasma species have the capacity to synthesize urease''' | ** '''Some yeasts and mycoplasma species have the capacity to synthesize urease''' | ||
** '''Although E. coli is a common cause of UTIs, only rare species of E. coli produce urease''' | ** '''<span style="color:#ff0000">Although E. coli is a common cause of UTIs, only rare species of E. coli produce urease</span>''' | ||
* '''Pathogenesis''' | * '''Pathogenesis''' | ||
** '''Occur more often in females''' than males by a ratio of 2:1 '''because infection stones occur most commonly in those prone to frequent UTIs.''' | ** '''Occur more often in females''' than males by a ratio of 2:1 '''because infection stones occur most commonly in those prone to frequent UTIs.''' | ||
Line 342: | Line 312: | ||
** '''Spinal cord–injured patients are at particular risk for both infection and metabolic stones owing to neurogenic urinary tract dysfunction and hypercalciuria related to immobility''' | ** '''Spinal cord–injured patients are at particular risk for both infection and metabolic stones owing to neurogenic urinary tract dysfunction and hypercalciuria related to immobility''' | ||
* '''Commonly produce staghorn stones; however, other crystals, including cystine, calcium oxalate monohydrate, and uric acid, can assume a staghorn configuration''' | * '''Commonly produce staghorn stones; however, other crystals, including cystine, calcium oxalate monohydrate, and uric acid, can assume a staghorn configuration''' | ||
== Other stones == | == Other stones == | ||
Line 350: | Line 319: | ||
* '''Predominately composed (65%) of organic proteins''', sugars, and glucosaminses, unlike other stones that have minimal organic material (2.5%) | * '''Predominately composed (65%) of organic proteins''', sugars, and glucosaminses, unlike other stones that have minimal organic material (2.5%) | ||
** Among the proteins incorporated into the matrix substance are Tamm-Horsfall protein, nephrocalcin, a γ-carboxyglutamic acid–rich protein, renal lithostathine, albumin, glycosaminoglycans, free carbohydrates, and a mucoprotein called matrix substance A | ** Among the proteins incorporated into the matrix substance are Tamm-Horsfall protein, nephrocalcin, a γ-carboxyglutamic acid–rich protein, renal lithostathine, albumin, glycosaminoglycans, free carbohydrates, and a mucoprotein called matrix substance A | ||
* ''' | * '''Risk factors (4)''' | ||
* '''Challenging to diagnose preoperatively, as they can mimic upper tract collecting system soft-tissue masses''' and require a high index of suspicion | *#'''Recurrent UTI by urea-splitting bacteria''' | ||
* '''Radiolucent on plain film x-ray''' | *#'''Previous stone formation''' | ||
*#'''Previous surgery due to urolithiasis''' | |||
*#'''Obstructive uropathy''' | |||
* '''Diagnosis and Evaluation''' | |||
**'''Imaging''' | |||
***'''Challenging to diagnose preoperatively, as they can mimic upper tract collecting system soft-tissue masses''' and require a high index of suspicion | |||
*** '''Radiolucent on plain film x-ray''' | |||
=== Xanthine stones === | === Xanthine stones === | ||
Line 369: | Line 344: | ||
** Subjects who abuse laxatives are chronically dehydrated, resulting in intracellular acidosis. In addition, urinary sodium is low from sodium loss as a result of the laxatives. In this environment, urate preferentially complexes with the abundant ammonium rather than sodium and produces ammonium acid urate stones. | ** Subjects who abuse laxatives are chronically dehydrated, resulting in intracellular acidosis. In addition, urinary sodium is low from sodium loss as a result of the laxatives. In this environment, urate preferentially complexes with the abundant ammonium rather than sodium and produces ammonium acid urate stones. | ||
=== Medication associated stones === | === Medication associated stones[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1508366] === | ||
*'''Lotta Good Drugs Cause Calculi FIT TEST (12):''' | *'''<span style="color:#0000ff">Lotta Good Drugs Cause Calculi FIT TEST (12):''' | ||
*# ''' | *# '''<span style="color:#0000ff">L<span style="color:#ff0000">axatives''' | ||
*# ''' | *# '''<span style="color:#0000ff">G<span style="color:#ff0000">uaifenesin''' | ||
*# '''Vitamin D''' | *# '''<span style="color:#ff0000">Vitamin <span style="color:#0000ff">D''' | ||
*# '''Vitamin C''' | *# '''<span style="color:#ff0000">Vitamin <span style="color:#0000ff">C</span>''' in high doses is converted to oxalate and may induce hyperoxaluria | ||
*# ''' | *# '''<span style="color:#0000ff">C<span style="color:#ff0000">arbonic anhydrase inhibitors''' | ||
*#* May be associated with the formation of calcium-based calculi, '''particularly calcium phosphate''' | *#*E.g. acetazolamide | ||
*# ''' | *#*May be associated with the formation of calcium-based calculi, '''particularly calcium phosphate''' | ||
*# '''<span style="color:#0000ff">F<span style="color:#ff0000">urosemide''' | |||
*#* '''Thiazides''' cause intracellular acidosis and '''subsequent hypocitraturia''' | *#* '''Thiazides''' cause intracellular acidosis and '''subsequent hypocitraturia''' | ||
*# ''' | *# '''<span style="color:#0000ff">I<span style="color:#ff0000">ndinavir''' | ||
*#* '''MOA: protease inhibitor''' | *#* '''MOA: protease inhibitor''' | ||
*#* '''Used in patients with HIV/AIDS.''' | *#* '''Used in patients with HIV/AIDS.''' | ||
Line 385: | Line 361: | ||
*#* '''Now infrequently used''', replaced with newer generation agents. Kidney stone formation has been associated with a number of newer anti-retroviral agents. | *#* '''Now infrequently used''', replaced with newer generation agents. Kidney stone formation has been associated with a number of newer anti-retroviral agents. | ||
*#* '''Radiolucent on plain film and may not be seen on CT''' | *#* '''Radiolucent on plain film and may not be seen on CT''' | ||
*# ''' | *# '''<span style="color:#0000ff">T<span style="color:#ff0000">opiramate''' | ||
*#* Used to treat epilepsy and prevent migraines | *#* '''MOA: carbonic anhydrase inhibitor''' | ||
*#*Used to treat epilepsy and prevent migraines | |||
*#* Creates a chronic intracellular acidosis resulting '''in a urinary milieu similar to distal RTA''' with hyperchloremic acidosis, high urine pH, extremely low urinary citrate, and hypercalciuria. | *#* Creates a chronic intracellular acidosis resulting '''in a urinary milieu similar to distal RTA''' with hyperchloremic acidosis, high urine pH, extremely low urinary citrate, and hypercalciuria. | ||
*#* '''Treatment may be potassium citrate''' or cessation of the medication if possible. | *#* '''Treatment may be potassium citrate''' or cessation of the medication if possible. | ||
*# ''' | *# '''<span style="color:#0000ff">T<span style="color:#ff0000">riamterene''' | ||
*#* MOA: potassium-sparing diuretic | *#* '''MOA: potassium-sparing diuretic''' | ||
*#* Used for the treatment of hypertension | *#* Used for the treatment of hypertension | ||
*#* '''Radiolucent''' | *#* '''Radiolucent''' | ||
*# ''' | *# '''<span style="color:#0000ff">E<span style="color:#ff0000">phedrine''' | ||
*# ''' | *# '''<span style="color:#0000ff">S<span style="color:#ff0000">ilicates''' | ||
*# ''' | *# '''<span style="color:#0000ff">T<span style="color:#ff0000">MP/SMX''' | ||
== Anatomic predisposition to stones == | == Anatomic predisposition to stones == |